EP1979054A1 - Compositions d'emulsion d'eau dans l'huile contenant des elastomeres de siloxane - Google Patents

Compositions d'emulsion d'eau dans l'huile contenant des elastomeres de siloxane

Info

Publication number
EP1979054A1
EP1979054A1 EP06844620A EP06844620A EP1979054A1 EP 1979054 A1 EP1979054 A1 EP 1979054A1 EP 06844620 A EP06844620 A EP 06844620A EP 06844620 A EP06844620 A EP 06844620A EP 1979054 A1 EP1979054 A1 EP 1979054A1
Authority
EP
European Patent Office
Prior art keywords
skin
composition
emulsifying
crosslinked siloxane
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06844620A
Other languages
German (de)
English (en)
Inventor
Naohisa Yoshimi
Hidekazu Tanaka
Akihiro Ueda
Kosaku Yamada
Kara Joann Stump
Chu Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP1979054A1 publication Critical patent/EP1979054A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
    • A61K8/894—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A61K8/895—Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/594—Mixtures of polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to water in oil emulsion type skin care compositions containing a combination of emulsifying and non-emulsifying siloxane elastomers.
  • Such compositions are useful for delivering skin care actives in products with consumer acceptable aesthetics.
  • the amount and rate of aqueous phase released from the compositions upon spreading application to the skin can provide consumer acceptable aesthetics and non- greasy skin feel.
  • ⁇ particular skin care composition is also important. For example, as the level of commonly incorporated moisturizing agents such as glycerin increases, greasy skin feel also increased.
  • compositions that can provide smooth spreadability and water-like, fresh skin feel, with silky after-feel.
  • Previous skin care and cosmetic compositions incorporating silicone elastomers have been described, e.g., WO 02/03930, WO 02/03950; WO 02/03951; WO 02/03952; EP 1 166 746 Al; EP 1 068 851 Al; Japanese Laid Open Publication No. 2003-081757; and Japanese Laid Open Publication No. 2003-55141.
  • compositions said to provide the impression of freshness and "splash" of the aqueous ingredients upon rubbing are described.
  • compositions containing only silicone emulsifiers, or compositions using different silicone elastomer systems have not provided the level of aqueous content and release from the emulsion that the compositions of the present invention provide.
  • the present invention relates to water in oil emulsion compositions comprising: from about 0.1% to about 15% of a non-emulsifying crosslinked siloxane elastomer; from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of a solvent for the non-emulsifying and emulsifying crosslinked siloxane elastomers; optionally, from 0% to about 5% of an additional emulsifier; from about 50% to about 99% of aqueous phase; wherein when shear stress is applied to the composition during spreading on skin, aqueous phase is released from the emulsion.
  • the present invention also relates to methods of using such compositions to regulate the condition of mammalian skin.
  • Said methods generally contain the step of topically applying a safe and effective amount of the composition to the skin of a mammal needing such treatment.
  • FIGS. IA-B are micrographs of suitable embodiments of the invention.
  • Figs. 2A-C are micrographs of suitable embodiments of the invention.
  • Figs. 3A-C are micrographs of a comparative example.
  • Figs. 4-6 are plots of log shear stress (x-axis) versus log viscosity (y-axis) for three sutiable embodiments of the invention.
  • Fig. 7 is a plot of log shear stress (x-axis) versus log viscosity (y-axis) for a comparative example.
  • skin care products are those used to treat or care for, or somehow moisturize, improve, or clean the skin.
  • Products contemplated by the phrase “skin care products” include, but are not limited to moisturizers, personal cleansing products, occlusive drug delivery patches, nail polish, powders, wipes, hair conditioners, skin treatment emulsions, shaving creams and the like.
  • compositions of the present invention can include, consist essentially of, or consist of, the components of the present invention as well as other ingredients described herein.
  • Consisting essentially of means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods. All percentages, parts and ratios are based upon the total weight of the skin care compositions of the present invention, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore, do not include carriers or by-products that may be included in commercially available materials, unless otherwise specified. All publications cited herein are hereby incorporated by reference in their entirety.
  • keratinous tissue refers to keratin-containing layers disposed as the outermost protective covering of mammals (e.g., humans, dogs, cats, etc.) which includes, but is not limited to, skin, lips, hair, toenails, fingernails, cuticles, hooves, etc.
  • the term "dermatologically-acceptable,” as used herein, means that the compositions or components thereof so described are suitable for use in contact with mammalian keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like.
  • safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit, preferably a positive keratinous tissue appearance or feel benefit, or positive hair appearance or feel benefit, including independently or in combinations the benefits disclosed herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan.
  • smoothing and softening as used herein mean altering the surface of the keratinous tissue such that its tactile feel is improved.
  • Such silicone elastomers have been used to reduce the tackiness/stickiness associated with skin conditioning agents including glycerin.
  • the water in oil emulsion compositions of the present invention comprising a mixture of emulsified and non-emulsified siloxane elastomers can provide skin care compositions that contain an aqueous phase which, upon release from the emulsion when applied by spreading onto the skin, provide even better sensory benefits than heretofor believed possible.
  • the rate of aqueous phase release from the emulsions of the present invention can be controlled to provide the desired consumer aesthetic and sensory benefits.
  • increased levels of skin conditioning agents such as glycerin can be incorporated into the compositions of the present invention, without causing the, compositions to feel greasy or sticky when spread upon the skin.
  • compositions of the present invention are also useful for regulating the condition of skin and especially for regulating keratinous tissue condition.
  • Regulation of skin condition namely mammalian and in particular human skin condition, is often required due to conditions which may be induced or caused by factors internal and/or external to the body. Examples include, environmental damage, radiation exposure (including ultraviolet radiation), chronological aging, menopausal status (e.g., post-menopausal changes in skin), stress, diseases, etc.
  • regulating skin condition includes prophylactically regulating and/or therapeutically regulating skin condition, and may involve one or more of the following benefits: thickening of skin (i.e., building the epidermis and/or dermis and/or sub-dermal (e.g., subcutaneous fat or muscle) layers of the skin and where applicable the keratinous layers of the nail and hair shaft) to reduce skin atrophy, increasing the convolution of the dermal-epidermal border (also known as the rete ridges), preventing loss of skin elasticity (loss, damage and/or inactivation of functional skin elastin) such as elastosis, sagging, loss of skin recoil from deformation; non-melanin skin discoloration such as under eye circles, blotching (e.g., uneven red coloration due to, e.g., rosacea) (hereinafter referred to as "red blotchiness”), sallowness (pale color), discoloration caused by telan
  • compositions of the present invention provide additional benefits, including stability, absence of significant (consumer-unacceptable) skin irritation and good aesthetics.
  • compositions of the present invention contain a non-emulsifying cfosslinked siloxane elastomer; an emulsifying crosslinked siloxane elastomer; a solvent for the non- emulsifying and emulsifying crosslinked siloxane elastomers; optionally, an additional emulsifier; and aqueous water phase.
  • the compositions also preferably contain one or more skin care actives.
  • compositions herein may also include a wide variety of other ingredients.
  • compositions of the present invention are described in detail hereinafter.
  • An essential component of the present invention is a crosslinked organopolysiloxane elastomer. No specific restriction exists as to the type of curable organopolysiloxane composition that can serve as starting material for the crosslinked organopolysiloxane elastomer.
  • addition reaction-curing organopolysiloxane compositions which cure under platinum metal catalysis by the addition reaction between SiH-containing diorganopolysiloxane and organopolysiloxane having silicon-bonded vinyl groups; condensation-curing organopolysiloxane compositions which cure in the presence of an organotin compound by a dehydrogenation reaction between hydroxyl-terminated diorganopolysiloxane and SiH-containing diorganopolysiloxane; condensation-curing organopolysiloxane compositions which cure in the presence of an organotin compound or a titanate ester, by a condensation reaction between an hydroxyl-terminated diorganopolysiloxane and a hydrolyzable organosilane (this condensation reaction is exemplified by dehydration, alcohol-liberating, oxime-liberating, amine-liberating, amide-liberating, carboxyl-liberating, and ketone-liber
  • component (A) is the basic component of the siloxane elastomer-generating organopolysiloxane, and curing proceeds by the addition reaction of this component with component (B) under catalysis by component (C).
  • This component (A) must contain at least 2 silicon-bonded lower alkenyl groups in each molecule; an excellent cured product will not be obtained at few than two lower alkenyl groups because a network structure will not be formed.
  • Said lower alkenyl groups are exemplified by vinyl, allyl, and propenyl. While the lower alkenyl groups can be present at any position in the molecule, their presence at the molecular terminals is preferred.
  • the molecular structure of this component may be straight chain, branched straight chain, cyclic, or network, but a straight chain, possibly slightly branched, is preferred.
  • the molecular weight of the component is not specifically restricted, and thus the viscosity may range from low viscosity liquids to very high viscosity gums.
  • the viscosity at 25 degrees Centigrade be at least 100 centistokes.
  • organopolysiloxanes are exemplified by methylvinylsiloxanes, methylvinylsiloxane- dimethylsiloxane copolymers, dimethylvinylsiloxy-terminated dimethylpolysiloxanes, dimethylvinylsiloxy-terminated dimethylsiloxane-niethylphenylsiloxane copolymers, dimethylvinylsiloxy-terminated dimethylsiloxane-diphenylsiloxane-methylvinylsiloxane copolymers, trimethylsiloxy-terminated dimethylsiloxane-methylvinylsiloxane copolymers, trimethylsiloxy-terminated dimethylsiloxane-methylphenylsiloxane-methylvinylsiloxane copolymers, dimethylvinylsiloxy-terminated methyl(3,3,3-trifluoropropyl) polysiloxanes
  • Component (B) is an organopolysiloxane having at least 2 silicon-bonded hydrogen atoms in each molecule and is a crosslinker for component (A). Curing proceeds by the addition reaction of the silicon-bonded hydrogen atoms in this component with the lower alkenyl groups in component (A) under catalysis by component (C).
  • This component (B) must contain at least 2 silicon-bonded hydrogen atoms in each molecule in order to function as a crosslinker. Furthermore, the sum of the number of alkenyl groups in each molecule of component (A) and the number of silicon-bonded hydrogen atoms in each molecule of component (B) is to be at least 5. Values below 5 should be avoided because a network structure is then essentially not formed.
  • this component may be any of straight chain, branch-containing straight chain, cyclic, etc.
  • the molecular weight of this component is not specifically restricted, but it is preferred that the viscosity at 25 degrees Centigrade be 1 to 50,000 centistokes in order to obtain good miscibility with component (A). It is preferred that this component be added in a quantity such that the molar ratio between the total quantity of silicon-bonded hydrogen atoms in the instant component and the total quantity of all lower alkenyl groups in component (A) falls within the range of (1.5:1) to (20:1). It is difficult to obtain good curing properties when this molar ratio falls below 0.5:1.
  • Component (C) is a catalyst of the addition reaction of silicon-bonded hydrogen atoms and alkenyl groups, and is concretely exemplified by chloroplatinic acid, possibly dissolved in an alcohol or ketone and this solution optionally aged, chloroplatinic acid-olefin complexes, chloroplatinic acid-alkenylsiloxane complexes, chloroplatinic acid-diketone complexes, platinum black, and carrier-supported platinum.
  • This component is added preferably at 0.1 to 1,000 weight parts, and more preferably at 1 to 100 weight parts, as platinum-type metal proper per 1,000,000 weight parts of the total quantity of components (A) plus (B).
  • Other organic groups which may be bonded to silicon in the organopolysiloxane forming the basis for the above-described curable organopolysiloxane compositions are, for example, alkyl groups such as methyl, ethyl, propyl, butyl, and octyl; substituted alkyl groups such as 2-phenylethyl, 2-phenylpropyl, and 3,3,3-trifluoropropyl; aryl groups such as phenyl, tolyl, and xylyl; substituted aryl groups such as phenylethyl; and monovalent hydrocarbon groups substituted by, for example, the epoxy group, the carboxylate ester group, the mercapto group, etc.
  • organopolysiloxane elastomer powder examples are as follows: an organopolysiloxane composition as described above (additional-curable, condensation- curable, or peroxide-curable) is mixed with water in the presence of a surfactant (nonionic, anionic, cationic, or amphoteric), and, after mixing to homogeneity in a homomixer, colloid mill, homogenizer, propeller mixer, etc., this is cured by discharge into hot water (temperature at least 50 degrees Centigrade) and is then dried; the organopolysiloxane composition (addition-curable, condensation-curable, or peroxide-curable) is cured by spraying it directly into a heated current; the powder is obtained by curing a radiation-curable organopolysiloxane composition by spraying it under high energy radiation; the organopolysiloxane composition (addition-curable, condensation-curable, peroxide-
  • Suitable organopolysiloxane elastomer powders include vinyl dimethicone/methicone silesquioxane crosspolymers like Shin-Etsu's KSP-100, KSP-101, KSP-102, KSP-103, KSP-104, KSP- 105, hybrid silicone powders that contain a fluoroalkyl group like Shin-Etsu's KSP-200, and hybrid silicone powders that contain a phenyl group such as Shin-Etsu's KSP-300; and Dow Coming's DC 9506.
  • Preferred organopolysiloxane compositions are dimethicone/vinyl dimethicone crosspolymers.
  • dimethicone/vinyl dimethicone crosspolymers are supplied by a variety of suppliers including Dow Corning (DC 9040 and DC 9041), General Electric (SFE 839), Shin Etsu (KSG-15, 16, 18 [dimethicone /phenyl vinyl dimethicone crosspolymer]), and Grant Industries (GransilTM line of materials), and lauryl dimethicone/vinyl dimethicone crosspolymers supplied by Shin Etsu (e.g., KSG-21, KSG-210, KSG-310, KSG-320, KSG-41, KSG-42, KSG- 43, KSG-44, KSG-710 and KSG-810).
  • Shin Etsu e.g., KSG-21, KSG-210, KSG-310, KSG-320, KSG-41, KSG-42, K
  • compositions of the present invention comprise a combination of emulsifying and non-emulsifying crosslinked organopolysiloxane elastomer.
  • non-emulsifying defines crosslinked organopolysiloxane elastomer from which polyoxyalkylene units or polyglycerin units are absent.
  • emulsifying means crosslinked organopolysiloxane elastomer having at least one polyoxyalkylene (e.g., polyoxyethylene or polyoxypropylene) unit or polyglycerin unit.
  • Particularly useful emulsifying elastomers are polyoxyalkylene-modif ⁇ ed elastomers formed from divinyl compounds, particularly siloxane polymers with at least two free vinyl groups, reacting with Si-H linkages on a polysiloxane backbone.
  • the elastomers are dimethyl polysiloxanes crosslinked by Si-H sites on a molecularly spherical MQ resin.
  • the non-emulsifying cross-linked organopolysiloxane elastomers of the present invention are preferably further processed by subjecting them to a high shear (approximately 5,000 psi) treatment in the presence of a solvent for the siloxane elastomer via a Sonolator with or without recycling in 10 to 60 passes.
  • the emulsifying crosslinked organopolysiloxane elastomer is present in the compositions of the present invention at concentrations of from about 0.1% to about 15%, preferably from about 0.2% to about 5%, most preferably from about 0.2% to about 2% by weight.
  • the non-emulsifying crosslinked organopolysiloxane elastomer is present in the compositions of the present invention at concentrations of from about 0.1 to about 15%, preferably from about 0.1 to about 5%, most preferably from about 0.1 to about 2% by weight.
  • compositions of the present invention comprise a solvent for the crosslinked organopolysiloxane elastomer described above.
  • the solvent when combined with the cross- linked organopolysiloxane elastomer particles of the present invention, serves to suspend and swell the elastomer particles to provide an elastic, gel-like network or matrix.
  • the solvent for the cross-linked siloxane elastomer is liquid under ambient conditions, and preferably has a low viscosity to provide for improved spreading on the skin.
  • Concentrations of the solvent in the cosmetic compositions of the present invention will vary primarily with the type and amount of solvent and the cross-linked siloxane elastomer employed. Preferred concentrations of the solvent are from about 1% to about 50%, preferably from about 4% to about 50%, more preferably from about 5% to about 40%, by weight of the composition.
  • the solvent for the crosslinked siloxane elastomer comprises one or more liquid carriers suitable for topical application to human skin.
  • liquid carriers may be organic, silicone- containing or fluorine-containing, volatile or non-volatile, polar or non-polar, provided that the liquid carrier forms a solution or other homogenous liquid or liquid dispersion with the selected cross-linked siloxane elastomer at the selected siloxane elastomer concentration at a temperature of from about 28°C to about 250°C, preferably from about 28°C to about 100 0 C, preferably from about 28°C to about 78 0 C.
  • the solvent for the cross-linked siloxane elastomer preferably has a solubility parameter of from about 3 to about 13 (cal/cm 3 ) 05 , more preferably from about 5 to about 11 (cal/cm 3 ) 05 , most preferably from about 5 to about 9 (cal/cm 3 ) o s .
  • Solubility parameters for the liquid carriers or other materials, and means for determining such parameters are well known in the chemical arts. A description of solubility parameters and means for determining them are described by C. D. Vaughan, "Solubility Effects in Product, Package, Penetration and Preservation” 103 Cosmetics and Toiletries 47-69, October 1988; and C. D. Vaughan, "Using Solubility Parameters in Cosmetics Formulation", 36 J. Soc. Cosmetic Chemists 319-333, September/October, 1988, which articles are incorporated herein by reference.
  • the solvent preferably includes volatile, non-polar oils; non-volatile, relatively polar oils; non-volatile, non-polar oils; and non-volatile paraffinic hydrocarbon oils; each discussed more fully hereinafter.
  • non-volatile refers to materials that exhibit a vapor pressure of no more than about 0.2 mm Hg at 25°C at one atmosphere and/or to materials that have a boiling point at one atmosphere of at least about 300 0 C.
  • volatile refers to all materials that are not “non-volatile” as previously defined herein.
  • relatively polar means more polar than another material in terms of solubility parameter; i.e., the higher the solubility parameter the more polar the liquid.
  • non-polar typically means that the material has a solubility parameter below about 6.5 (cal/cm 3 ) 0 - 5 .
  • Non-polar, volatile oils tends to impart highly desirable aesthetic properties to the compositions of the present invention. Consequently, the non-polar, volatile oils are preferably utilized at a fairly high level.
  • Non-polar, volatile oils particularly useful in the present invention are selected from the group consisting of silicone oils; hydrocarbons; and mixtures thereof. Such non-polar, volatile oils are disclosed, for example, in Cosmetics, Science, and Technology, Vol. 1, 27-104 edited by Balsam and Sagarin, 1972.
  • the non-polar, volatile oils useful in the present invention may be either saturated or unsaturated, have an aliphatic character and be straight or branched chained or contain alicyclic or aromatic rings.
  • non-polar, volatile hydrocarbons examples include polydecanes such as isododecane and isodecane (e.g., Permethyl-99A which is available from Presperse Inc.) and the C7 -C8 through C12 -C15 isoparaffms (such as the Isopar Series available from Exxon Chemicals).
  • Non-polar, volatile liquid silicone oils are disclosed in U.S. Patent 4,781,917 issued to Luebbe et al. on Nov. 1, 1988. Additionally, a description of various volatile silicones materials is found in Todd et al., "Volatile Silicone Fluids for Cosmetics", Cosmetics and Toiletries, 91:27-32 (1976). Particularly preferred volatile silicone oils are selected from the group consisting of cyclic volatile silicones corresponding to the formula:
  • n is from about 3 to about 7; and linear volatile silicones corresponding to the formula:
  • Linear volatile silicones generally have a viscosity of less than about 5 centistokes at 25°C, whereas the cyclic silicones have viscosities of less than about 10 centistokes at 25 0 C.
  • Highly preferred examples of volatile silicone oils include cyclomethicones of varying viscosities, e.g., Dow Corning 200, Dow Corning 244, Dow Corning 245, Dow Coming 344, and Dow Corning 345, (commercially available from Dow Corning Corp.); SF-1204 and SF-1202 Silicone Fluids (commercially available from G.E. Silicones), GE 7207 and 7158 (commercially available from' General Electric Co.); and SWS- 03314 (commercially available from SWS Silicones Corp.).
  • the non-volatile oil is "relatively polar" as compared to the non-polar, volatile oil discussed above. Therefore, the non-volatile co-solvent is more polar (i.e., has a higher solubility parameter) than at least one of the non-polar, volatile oils.
  • Relatively polar, nonvolatile oils potentially useful in the present invention are disclosed, for example, in Cosmetics, Science, and Technology, Vol. 1, 27-104 edited by Balsam and Sagarin, 1972; U.S. Patents 4,202,879 issued to Shelton on May 13, 1980; and 4,816,261 issued to Luebbe et al. on Mar. 28, 1989.
  • Relatively polar, non- volatile oils useful in the present invention are preferably selected from the group consisting of silicone oils; hydrocarbon oils; fatty alcohols; fatty acids; esters of mono and dibasic carboxylic acids with mono and polyhydric alcohols; polyoxyethylenes, polyoxypropylenes, mixtures of poly oxy ethylene and polyoxypropylene ethers of fatty alcohols; and mixtures thereof.
  • the relatively polar, non-volatile co-solvents useful in the present invention may be either saturated or unsaturated, have an aliphatic character and be straight or branched chained or contain alicyclic or aromatic rings.
  • the relatively polar, non-volatile liquid co-solvent are selected from the group consisting of fatty alcohols having from about 12-26 carbon atoms; fatty acids having from about 12-26 carbon atoms; esters of monobasic carboxylic acids and alcohols having from about 14-30 carbon atoms; esters of dibasic carboxylic acids and alcohols having from about 10-30 carbon atoms; esters of polyhydric alcohols and carboxylic acids having from about 5-26 carbon atoms; ethoxylated, propoxylated, and mixtures of ethoxylated and propoxylated ethers of fatty alcohols with from about 12-26 carbon atoms and a degree of ethoxylation and propoxylation of below about 50; and mixtures thereof.
  • propoxylated ethers of C 14-Cl 8 fatty alcohols having a degree of propoxylation below about 50 esters of C2-C8 alcohols and C12-C26 carboxylic acids (e.g. ethyl myristate, isopropyl palmitate), esters of C12-C26 alcohols and benzoic acid (e.g.
  • Finsolv TN supplied by Finetex diesters of C2-C8 alcohols and adipic, sebacic, and phthalic acids (e.g., diisopropyl sebacate, diisopropyl adipate, di-n-butyl phthalate), polyhydric alcohol esters of C6-C26 carboxylic acids (e.g., propylene glycol dicaprate/dicaprylate, propylene glycol isostearate); and mixtures thereof. Even more preferred are branched-chain aliphatic fatty alcohols having from about 12-26 carbon atoms. 3.
  • Non-polar, Non- volatile oils in addition to the liquids discussed above, the solvent for the cross-linked siloxane elastomer may optionally include non-volatile, non-polar oils.
  • Typical non-volatile, non-polar emollients are disclosed, for example, in Cosmetics, Science, and Technology, Vol. 1, 27-104 edited by Balsam and Sagarin, 1972; U.S. Patents 4,202,879 issued to Shelton on May 13, 1980; and 4,816,261 issued to Luebbe et al. on Mar. 28, 1989.
  • the non- volatile oils useful in the present invention are essentially non-volatile polysiloxanes, paraffinic hydrocarbon oils, and mixtures thereof.
  • polysiloxanes useful in the present invention selected from the group consisting of polyalkylsiloxanes, polyarylsiloxanes, polyalkylarylsiloxanes, poly-ethersiloxane copolymers, and mixtures thereof.
  • examples of these include polydimethyl siloxanes having viscosities of from about 1 to about 100,000 centistokes at 25°C.
  • preferred non- volatile silicone emollients useful in the present compositions are the polydimethyl siloxanes having viscosities from about 2 to about 400 centistokes at 25° C.
  • Such polyalkylsiloxanes include the Viscasil series (sold by General Electric Company) and the Dow Corning 200 series (sold by Dow Corning Corp.)- Polyalkylarylsiloxanes include polymethylphenyl siloxanes having viscosities of from about 15 to about 65 centistokes at 25 0 C. These are available, for example, as SF 1075 methyl-phenyl fluid (sold by General Electric Company) and 556 Cosmetic Grade Fluid (sold by Dow Coming Corp.).
  • Non-volatile paraffinic hydrocarbon oils useful in the present invention include mineral oils and certain branched-chain hydrocarbons. Examples of these fluids are disclosed in U.S. Patent 5,019,375 issued to Tanner et al. on May 28, 1991. Preferred mineral oils have the following properties:
  • Preferred branched chain hydrocarbon oils have the following properties:
  • Suitable branched-chain hydrocarbons include Permethyl 103 A, which contains an average of about 24 carbon atoms; Permethyl 104A, which contains an average of about 68 carbon atoms; Permethyl 102A, which contains an average of about 20 carbon atoms; all of which may be purchased from Permethyl Corporation; and Ethylflo 364 which contains a mixture of 30 carbon atoms and 40 carbon atoms and may be purchased from Ethyl Corp. Additional solvents useful herein are described in US Patent 5,750,096 to Gerald J.
  • the cosmetic compositions of the present invention comprise an aqueous phase comprising from about 50% to about 99%, preferably from about 50% to about 95%, more preferably from about 65% to about 90% by weight of the composition.
  • compositions of the present invention are water in oil emulsions.
  • aqueous phase there is weak bonding of aqueous phase to oil phase.
  • This can permit the composition to transform upon application, e.g., to provide a water-splash sensation during spreading or rubbing upon the skin.
  • the composition is in the form of a gel or cream.
  • the finger shear stress is believed to break the emulsion, thereby releasing the aqueous phase from the emulsion. This provides good consumer sensory benefit, as the aqueous phase so released is perceptible to the touch as well as visually.
  • the visually perceptible release of the aqueous phase may be characterized by the Microscopy Method as presented in the Test Methods.
  • the microscopy method is a microscope-assisted visual analysis of the presence and size of the aqueous domains emulsified within the oil phase.
  • the emulsion is subjected to timed increments of shear after which a micrograph of the emulsion is taken.
  • a visually perceptible release of the aqueous phase occurs when an amorphous aqueous region having a maximum linear dimension of at least about 10 microns becomes visible at 50Ox magnification within about 1 minute of shear.
  • the visually perceptible release of the aqueous phase occurs when an amorphous region of water having a size of at least about 25, 50, or 75 microns becomes visible at 500x magnification within about 1 minute of shear. In another suitable embodiment, the visually perceptible release of the aqueous phase occurs when an amorphous region of water having a size of at least 10 microns becomes visible at 500x magnification within about 45 second, 30 second, or 15 seconds of shear.
  • the visually perceptible release of the aqueous phase may be characterized by phase separation after milling according to the Milling Method provided in the Test Methods.
  • the milling method involves the bulk milling of a 30g sample of the emulsion.
  • a visually perceptible release of a portion of the aqueous phase occurs when at least about 0.5 g of the aqueous phase separates after 1 minute of milling at a rate of 24000 rpm. In further embodiments, at least about 1.0 g, 2.5 g, or 5.0 g of the aqueous phase separates after 1 minute of milling at a rate of 24000 rpm.
  • a visually perceptible release of a portion of the aqueous phase occurs when at least 0.25 g of the aqueous phase separates after 1 minute of milling at a rate of 13500 rpm.
  • the composition may result in the separation of at least about a 0.5 g portion of the aqueous phase after 1 minute of milling at a rate of 24000 rpm while yielding no visually perceptible release of the aqueous phase ⁇ i.e., ⁇ O.lg of aqueous phase) after 1 minute of milling at a rate of 8000 rpm.
  • Such an embodiment is believed to have suitable shelf and processing stability while still exhibiting a perceptible release of the aqueous phase during typical skin application.
  • the tactilely perceptible release of the aqueous phase may be characterized by a viscosity drop as measured in the Rheological Method provided in the Test Methods.
  • the rheological method involves applying a controlled stress to a sample of the emulsion to generate a rheology profile of the log of viscosity (y-axis) versus the log of shear stress (x-axis).
  • the plot of viscosity versus shear yields a sharp decrease in viscosity at a critical shear stress.
  • the slope of the region of the plot exhibiting a sharp decrease is less than about -5.
  • slope of the region of the plot exhibiting a sharp decrease is less than about -10, - 25, -50, -75, or -100.
  • the amount of aqueous phase released from the emulsion and the rate at which the aqueous phase is released from the emulsion can be controlled, depending upon how the oil phase is bonded to the aqueous phase in the emulsion.
  • the amount of aqueous phase released from the emulsion and the rate at which it is released from the emulsion can be controlled, for example, by incorporating an additional emulsif ⁇ er for dispersing the aqueous phase as described below, by changing the level of the emulsifying crosslinked siloxane elastomer within the claimed range, and by varying the water/oil phase ratio.
  • the water- in-oil emulsions of the present invention can optionally contain an emulsifier in addition to an emulsifying elastomer.
  • the composition may contain from about 0% to about 5%, preferably from 0.01% to about 5% additional emulsifier, more preferably from about 0.1% to about 3%, still more preferably from about 0.1% to about 2%, emulsifier by weight of the composition.
  • the additional emulsifier if present helps disperse and suspend the aqueous phase within the continuous silicone phase.
  • a wide variety of emulsifying agents can be employed herein to form the preferred water- in-silicone emulsion.
  • emulsifying agents can be used in the composition, provided that the selected emulsifying agent is chemically and physically compatible with components of the composition of the present invention, and provides the desired dispersion characteristics.
  • Suitable emulsifiers include silicone emulsifiers, non- silicon-containing emulsifiers, and mixtures thereof, known by those skilled in the art for use in topical personal care products.
  • these emulsifiers Preferably these emulsifiers have an HLB value of or less than about 14, more preferably from about 2 to about 14, and still more preferably from about 4 to about 10.
  • Emulsifiers having an HLB value outside of these ranges can be used in combination with other emulsifiers to achieve an effective weighted average HLB for the combination that falls within these ranges.
  • Silicone emulsifiers are preferred.
  • a wide variety of silicone emulsifiers are useful herein. These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants.
  • Useful silicone emulsifiers include dimethicone copolyols. These materials are polydimethyl siloxanes which have been modified to include polyether side chains such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains, and polyether chains containing moieties derived from both ethylene oxide and propylene oxide.
  • Other examples include alkyl-modified dimethicone copolyols, i.e., compounds which contain C2-C30 pendant side chains.
  • Still other useful dimethicone copolyols include materials having various cationic, anionic, amphoteric, and zwitterionic pendant moieties.
  • Nonlimiting examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers herein include polydimethylsiloxane polyether copolymers with pendant polyethylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed polyethylene oxide and polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed poly(ethylene)(propylene)oxide sidechains, polydimethylsiloxane polyether copolymers with pendant organobetaine sidechains, polydimethylsiloxane polyether copolymers with pendant carboxylate sidechains, polydimethylsiloxane polyether copolymers with pendant quaternary ammonium sidechains; and also further modifications of the preceding copolymers containing pendant C2-C30 straight, branched, or cyclic alky
  • dimethicone copolyols useful herein sold by Dow Corning Corporation are Dow Corning® 190, 193, Q2-5220, 2501 Wax, 2-5324 fluid, and 3225C (this later material being sold as a mixture with cyclomethicone).
  • Ceryl dimethicone copolyol is commercially available under the trade name AB IL® EM-90, and also available as a mixture with polyglyceryl-4 isostearate (and) hexyl laurate and is sold under the tradename ABIL® WE-09 (available from Goldschmidt). Cetyl dimethicone copolyol is also commercially available as a mixture with hexyl laurate (and) polyglyceryl-3 oleate (and) cetyl dimethicone and is sold under the tradename ABIL® WS-08 (also available from Goldschmidt).
  • dimethicone copolyol is commercially available under the trade names KF-6028, KF-6104, KF-6105, and KF-6106 (from Shin-Etsu).
  • dimethicone copolyols also include lauryl dimethicone copolyol, lauryl polydimethylsiloxyethyl dimethicone copolyol, dimethicone copolyol acetate, dimethicone copolyol adipate, dimethicone copolyolamine, dimethicone copolyol behenate, dimethicone copolyol butyl ether, dimethicone copolyol hydroxy stearate, dimethicone copolyol isostearate, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyoly
  • Dimethicone copolyol emulsif ⁇ ers useful herein are described, for example, in U.S. Patent No. 4,960,764, to Figueroa, Jr. et al.; European Patent No. EP 330,369, to SaNogueira; G.H. Damns, et al., "New Formulation Possibilities Offered by Silicone Copolyols," Cosmetics & Toiletries, vol. 110, pp. 91-100, March 1995; M.E. Carlotti et al., "Optimization of W/O-S Emulsions And Study Of The Quantitative Relationships Between Ester Structure And Emulsion Properties," J.
  • non-silicone-containing emulsif ⁇ ers useful herein are various non-ionic and anionic emulsifying agents such as sugar esters and polyesters, alkoxylated sugar ⁇ esters and polyesters, C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated derivatives of C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated ethers of C1-C30 fatty alcohols, polyglyceryl esters of C1-C30 fatty acids, C1-C30 esters of polyols, C1-C30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, and mixtures thereof.
  • Skin Care Active such as sugar esters and polyesters, alkoxylated sugar ⁇ esters and polyesters, C1-C30 fatty acid esters of C
  • compositions of the present invention preferably also include at least one skin care active. Actives that are typically characterized as "water-soluble” as well as actives that are typically characterized as “oil-soluble” are suitable for formulation herein. Without being bound by theory, it is believed the present compositions provide versatility in formulating a variety of actives.
  • the actives useful herein can be categorized by the benefit they provide or by their postulated mode of action. However, it is to be understood that the actives useful herein can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active to that particular application or applications listed.
  • Non-limiting examples of skin care actives suitable herein include niacinamide, hexamidine compounds, whitening actives, peptides, sugar amines, and mixtures thereof.
  • Niacinamide (or another solid at ambient temperature vitamin B 3 compound that is soluble in a solvent) is a preferred skin care active for use herein.
  • the present invention preferably includes from about 2% to about 30%, more preferably from about 2% to about 20%, even more preferably from about 2% to about 10% of a vitamin B3 compound.
  • niacinamide means a compound having the formula:
  • the niacinamide may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • the vitamin B3 compound is preferably substantially pure, more preferably essentially pure.
  • compositions of the present invention comprise a safe and effective amount of one or more hexamidine and its salts. More preferably, the hexamidine is hexamidine diisethionate.
  • hexamidine includes any isomers and tautomers of such and is commercially available as hexamidine diisethionate under the tradename Elestab® HPlOO from Laboratoires Serobiiquess (Pulnoy, France).
  • the hexamidine preferably comprises from about 0.0001-25% by weight of the composition, more preferably from about 0.001% to about 10%, more preferably from about 0.01% to about 5%, and most preferably from about 0.02% to about 2.5%.
  • the present compositions may contain a whitening agent.
  • the whitening agent useful herein refers to active ingredients that not only alter the appearance of the skin, but further improve hyperpigmentation as compared to pre-treatment.
  • Useful whitening agents useful herein include ascorbic acid compounds, vitamin B 3 compounds, azelaic acid, butyl hydroxy anisole, gallic acid and its derivatives, hydroquinoine, kojic acid, arbutin, mulberry extract, undecylenoyl phenylalanine, and mixtures thereof.
  • Use of combinations of whitening agents are also believed to be advantageous in that they may - provide whitening benefit through different mechanisms.
  • compositions When used, the compositions preferably contain from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, by weight of the composition, of a whitening agent.
  • Ascorbic acid compounds are useful whitening agents, and have the formula (I):
  • the ascorbic acid compound useful herein is an ascorbic acid salt or derivative thereof, such as the non-toxic alkali metal, alkaline earth metal and ammonium salts commonly known by those skilled in the art including, but not limited to, the sodium, potassium, lithium, calcium, magnesium, barium, ammonium and protamine salts which are prepared by methods well known in the art. More preferably, the ascorbic acid salt useful herein is a metal ascorbate having the following formula (II):
  • R and R are independently selected from hydrogen and linear or branched alkyl of 1 to about 8 carbons; M is a metal; and x is an integer of from 1 to about 3. More 2 3 preferably, R and R are independently selected from hydrogen and linear or branched alkyl of 1 to about 3 carbons; M is sodium, potassium, magnesium, or calcium.
  • Examples of other preferred ascorbic acid salts having formula (II) include monovalent metal salts (e.g., sodium ascorbate, potassium ascorbate), divalent metal salts (e.g., magnesium ascorbate, calcium ascorbate) and trivalent metal salts (e.g., aluminum ascorbate) of ascorbic acid.
  • monovalent metal salts e.g., sodium ascorbate, potassium ascorbate
  • divalent metal salts e.g., magnesium ascorbate, calcium ascorbate
  • trivalent metal salts e.g., aluminum ascorbate
  • the ascorbic acid salt useful herein is a water soluble ascorbyl ester having the following formula (III):
  • A is sulfate or phosphate
  • R and R are independently selected from hydrogen and linear or branched alkyl of 1 to about 8 carbons
  • M is a metal
  • y is an integer of 1 to about
  • R and R are independently selected from hydrogen and linear or
  • M is sodium, potassium, magnesium, or calcium.
  • Another particularly preferred ascorbic acid compound is 2-o- ⁇ -D-glucopyranosyl-L- ascorbic acid, usually referred to as L-ascorbic acid 2-glucoside or ascorbyl glucoside, and its metal salts.
  • L-ascorbic acid 2-glucoside or ascorbyl glucoside and its metal salts.
  • Such compounds are available from Hayashibara.
  • Magnesium ascorbyl phosphate is a stable form of vitamin C. In- vivo, it is converted to
  • Vitamin C It is soluble and stable in a variety of solvents including water, propylene glycol,
  • Exemplary water soluble salt derivatives include, but are not limited to, L-ascorbic acid
  • L-ascorbyl phosphate ester salts such as sodium L-ascorbyl phosphate, potassium
  • L-ascorbyl phosphate magnesium L-ascorbyl phosphate, calcium L-ascorbyl phosphate, aluminum L-ascorbyl phosphate.
  • L-ascorbyl sulfate ester salts can also be used. Examples are sodium L-ascorbyl sulfate, potassium L-ascorbyl sulfate, magnesium L-ascorbyl sulfate, calcium L-ascorbyl sulfate and aluminum L-ascorbyl sulfate.
  • Undecylenoyl Phenylalanine is the substituted amino acid that is also suitable for use herein as a whitening agent.
  • Peptides including but not limited to, di-, tri-, terra-, and pentapeptides and derivatives thereof, may be included in the compositions of the present invention in amounts that are safe and effective.
  • peptides refers to both the naturally occurring peptides and synthesized peptides. Also useful herein are naturally occurring and commercially available compositions that contain peptides.
  • Suitable dipeptides for use herein include Carnosine (beta-ala-his).
  • Suitable tripeptides for use herein include, gly-his-lys, arg-lys-arg, his-gly-gly.
  • Preferred tripeptides and derivatives thereof include palmitoyl-gly-his-lys, which may be purchased as Biopeptide CL®
  • a preferred commercially available pentapeptide derivative-containing composition is Matrixyl®, which contains 100 ppm of palmitoyl-lys-thr-thr-lys-ser (pal-KTTKS, commercially available from Sederma, France).
  • Other preferred peptides include palmitoyl-lysine-threonine (pal-KT) and palmitoyl-glycine-glutamine-proline-arginine (pal-GQPR, available in a composition known as RIGIN ® ), also available from Sederma, France.
  • peptides are preferably included in amounts of from about lxl ⁇ "6 % to about 10%, more preferably from about lxl ⁇ "6 % to about 0.1%, even more preferably from about lxl ⁇ ⁇ 5 % to about 0.01%, by weight of the composition.
  • the compositions preferably contain from about 0.1% to about 5%, by weight of the composition, of such peptides.
  • the compositions preferably contain from about 0.0001% to about 10%, of palmitoyl-lys-thr-thr-lys-ser and/or Biopeptide CL® peptide-containing composition.
  • compositions of the present invention may include a safe and effective amount of a sugar amine, whicrrare also known as amino sugars.
  • sugar amine refers to an amine derivative of a six-carbon sugar.
  • the composition contains from about
  • sugar amines examples include glucosamine, N-acetyl glucosamine, mannosamine, N-acetyl mannosamine, galactosamine, N-acetyl galactosamine. Preferred for use herein is glucosamine. Additionally, combinations of two or more sugar amines may be used.
  • Skin Conditioning Agent glucosamine, N-acetyl glucosamine, mannosamine, N-acetyl mannosamine, galactosamine, N-acetyl galactosamine.
  • compositions of the present invention include from about 1% to about 60%, by weight of the composition, of a skin conditioning agent.
  • the composition includes from about 2% to about 50%, more preferably from about 5% to about 40%, by weight of the composition, of the skin conditioning agent.
  • compositions with a high percentage of a skin conditioning agent may be perceived as greasy or tacky by a user. It has been surprisingly found that compositions of the present invention may comprise a relatively high percentage (e.g., greater than 25%, by weight of the composition) of a skin conditioning agent without an appreciable increase in the perceived greasiness or tackiness.
  • Suitable skin conditioning agent for use herein include polyhydric alcohols such as polyalkylene glycols.
  • Preferred for use herein are alkylene polyols and their derivatives.
  • Examples of polyhydric alcohols useful herein include propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, trehalose, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, 1,2,6-hexenetriol, glycerin, 1,2-hexanediol, pentylene glycol, ethoxylated glycerin, propoxylated glycerin, butanetriol, and mixtures thereof.
  • a preferred polyhydric alcohol for use herein is glycerin.
  • the skin conditioning agent for use herein may be derived from any traditional means of manufacture and methods of purification.
  • compositions of the present invention may further include one or more thickening agents.
  • the composition preferably includes from about 0.1% to about 5%, more preferably from about 0.1% to about 4%, and still more preferably from about 0.25% to about 3%, by weight of the composition of the thickening agent.
  • Nonlimiting classes of thickening agents include those selected from the following: a) Carboxylic Acid Polymers These polymers are crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol.
  • carboxylic acid polymers useful herein include the carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol.
  • the carbomers are available as the Carbopol® 900 series from B.F. Goodrich
  • carboxylic acid polymeric agents include copolymers of Cio- 3 o alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain (i.e., Ci -4 alcohol) esters, wherein the crosslinking agent is an allyl ether of sucrose or pentaerytritol.
  • these copolymers are known as aery lates/C 10-30 alkyl acrylate crosspolymers and are commercially available as Carbopol® 1342, Carbopol® 1382, PEMULEN TR-I, and PEMULEN TR-2, from B.F. Goodrich.
  • examples of carboxylic acid polymer thickeners useful herein are those selected from carbomers, acrylates/Cio-C3o alkyl acrylate crosspolymers, and mixtures thereof.
  • compositions of the present invention can optionally contain crosslinked polyacrylate polymers useful as thickeners or gelling agents including both cationic and nonionic polymers, with the cationics being generally preferred, c) Polyacrylamide Polymers
  • the compositions of the present invention can optionally contain polyacrylamide polymers, especially nonionic polyacrylamide polymers including substituted branched or unbranched polymers. More preferred among these polyacrylamide polymers is the nonionic polymer given the CTFA designation polyacrylamide and isoparaffm and laureth-7, available under the Tradename Sepigel 305 from Seppic Corporation (Fairfield, NJ).
  • Other polyacrylamide polymers useful herein include multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids. Commercially available examples of these multi-block copolymers include HYPAN SR150H, SS500V, SS500W, SSSAlOOH, from Lipo Chemicals, Inc., (Patterson, NJ).
  • Polysaccharides refer to gelling agents which contain a backbone of repeating sugar (i.e., carbohydrate) units.
  • Nonlimiting examples of polysaccharide gelling agents include those selected from cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof.
  • alkyl substituted celluloses are also useful herein.
  • the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C10-C30 straight chain or branched chain alkyl group through an ether linkage.
  • these polymers are ethers of C1 0 -C 30 straight or branched chain alcohols with.hydroxyalkylcelluloses.
  • alkyl groups useful herein include those selected from stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, cocoyl (i.e.
  • alkyl groups derived from the alcohols of coconut oil palmityl, oleyl, linoleyl, linolenyl, ricinoleyl, behenyl, and mixtures thereof.
  • Preferred among the alkyl hydroxyalkyl cellulose ethers is the material given the CTFA designation cetyl hydroxyethylcellulose, which is the ether of cetyl alcohol and hydroxyethylcellulose. This material is sold under the tradename Natrosol® CS Plus from Aqualon Corporation (Wilmington, DE).
  • scleroglucans which are a linear chain of (1-3) linked glucose units with a (1-6) linked glucose every three units, a commercially available example of which is ClearogelTM CSl 1 from Michel Mercier Products Inc. (Mountainside, NJ).
  • ClearogelTM CSl 1 from Michel Mercier Products Inc. (Mountainside, NJ).
  • thickening and gelling agents useful herein include materials which are primarily derived from natural sources.
  • Nonlimiting examples of these gelling agent gums include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.
  • compositions of the present invention may, in some embodiments, contain a particulate material to modify skin feel or appearance.
  • suitable particulate materials are disclosed in U.S. Patent No. 5,997,887, to Ha, et al.
  • Inorganic particulate materials e.g., TiO 2 , ZnO, or ZrO 2 are commercially available from a number of sources.
  • a suitable particulate material contains the material available from U.S. Cosmetics (TRONOX TiO 2 series, SAT-T CR837, a ratile TiO 2 ).
  • particulate materials with inorganic chemical combination are, COVERLEAF AR-80 available in Catalysts and Chemicals Ind. Co. Ltd.
  • particulate matearials are present in the composition in levels of from about 0.01% to about 20%, more preferably from about 0.05% to about 15%, still more preferably from about 0.1% to about 12%, by weight of the composition.
  • Suitable organic powders/fillers include, but are not limited, to polymeric particles chosen from the methylsilsesquioxane resin microspheres such as for example those sold by Toshiba silicone under the name Tospearl 145A; microspheres of polymethylmethacrylates such as those sold by Seppic under the name Micropearl M 100; the spherical particles of crosslinked polydimethylsiloxanes, especially such as those sold by Dow Corning Toray Silicone under the name Trefil E 506C or Trefil E 505C, sphericle particles of polyamide and more specifically Nylon 12, especially such as those sold by Atochem under the name Orgasol 2002D Nat C05, polystyerene microspheres such as for example those sold by Dyno Particles under the name Dynospheres, ethylene acrylate copolymer sold by Kobo under the name FloBead EA209 and mixtures thereof.
  • polymeric particles chosen from the methylsilsesquioxane resin micro
  • the particulates may be hydrophobically treated to be more easily dispersed in the delivery vehicle.
  • it may be useful to treat the pigments with a material that is compatible with a silicone phase.
  • Particularly useful hydrophobic pigment treatments for use in water-in-silicone emulsions include polysiloxane treatments such as those disclosed in U.S. Patent 5,143,722, incorporated herein by reference in its entirety.
  • Mixtures of the same or different particulates having different particle sizes are also useful herein (e.g., incorporating a TiO2 having a primary particle size of from about 100 nm to about 400 nm with a TiO2 having a primary particle size of from about 10 nm to about 50 nm).
  • Optional Ingredients e.g., incorporating a TiO2 having a primary particle size of from about 100 nm to about 400 nm with a TiO2 having a primary particle size of from about 10 nm to about 50 nm.
  • compositions of the present invention may contain one or more additional skin care actives.
  • additional components should be suitable for application to keratinous tissue, that is, when incorporated into the composition they are suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound medical judgment.
  • Non- limiting examples of additional skin care active ingredients that may be used in the present invention include sunscreen actives, oil-soluble terpene alcohols, phytosterols, oil- soluble vitamin compounds, additional vitamin B 3 compounds, oil-soluble vitamin compounds, emollients and occlusives, dehydroacetic acid, anti-acne actives, beta-hydroxy acids, chelators, flavonoids, anti-inflammatory agents, anti-cellulite agents, topical anesthetics, desquamation actives, anti-oxidants/radical scavengers, topical anesthetics, tanning actives, skin soothing and skin healing agents, anti-microbial and antifungal agents, and mixtures thereof.
  • sunscreen actives oil-soluble terpene alcohols, phytosterols, oil- soluble vitamin compounds, additional vitamin B 3 compounds, oil-soluble vitamin compounds, emollients and occlusives, dehydroacetic acid, anti-acne actives, beta-hydroxy acids, chelators, flavonoids
  • CTFA Cosmetic Ingredient Handbook describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention.
  • these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents, etc.
  • the actives useful herein can be categorized by the benefit they provide or by their postulated mode of action. However, it is to be understood that the actives useful herein can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active to that particular application or applications listed.
  • compositions of the subject invention may optionally contain a sunscreen active.
  • sunscreen active includes both sunscreen agents and physical sunblocks. Suitable sunscreen actives may be organic or inorganic.
  • Inorganic sunscreens useful herein include the following metallic oxides; titanium dioxide having an average primary particle size of from about 15 nm to about 100 nm, zinc oxide having an average primary particle size of from about 15 nm to about 150 nm, zirconium oxide having an average primary particle size of from about 15 nm to about 150 nm, iron oxide having an average primary particle size of from about 15 nm to about 500nm, and mixtures thereof.
  • the inorganic sunscreens are present in the amount of from about 0.1% to about 20%, preferably from about 0.5% to about 10%, more preferably from about 1% to about 5%, by weight of the composition.
  • a wide variety of conventional organic sunscreen actives are suitable for use herein.
  • Particulary preferred organic sunscreen actives useful in the compositions useful in the subject invention are homosalate, octocrylene, 2-ethylhexyl-p- methoxycinnamate (commercially available as PARSOL MCX), phenyl benzimidazole sulfonic acid, 2-hydroxy-4-methoxybenzophenone (Benzophenone-3), 2-ethylhexyl-salicylate, and mixtures thereof.
  • More preferred organic sunscreen actives useful in the compositions useful in the subject invention are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoyl-methane, 2-hydroxy-4- methoxybenzb-phenone, 2-phenylbenzimidazole-5-sulfonic acid, octyldimethyl-p-aminobenzoic acid, octocrylene, zinc oxide, titanium dioxide, and mixtures thereof.
  • a safe and effective amount of the organic sunscreen active is used, typically from about 1% to about 20%, more typically from about 2% to about 10% by weight of the composition. Exact amounts will vary depending upon the sunscreen or sunscreens chosen and the desired Sun Protection Factor (SPF).
  • SPF Sun Protection Factor
  • oil-soluble terpene alcohols examples include farnesol, derivatives of farnesol, isomers of farnesol, geraniol, derivatives of geraniol, isomers of geraniol, phytantriol, derivatives of phytantriol, isomers of phytantriol, and mixtures thereof.
  • farnesol is a naturally occurring substance which is believed to act as a precursor and/or intermediate in the biosynthesis of squalene and sterols, especially cholesterol.
  • Farnesol is also involved in protein modification and regulation (e.g., farnesylation of proteins), and there is a cell nuclear receptor which is responsive to farnesol.
  • farnesol is [2E,6E]-3,7,ll-trimethyl-2,6,10-dodecatrien-l-bl and as used herein "farnesol” includes isomers and tautomers of such.
  • Farnesol is commercially available, e.g., under the names farnesol (a mixture of isomers from Dragoco, 10 Gordon Drive, Totowa, New Jersey) and trans-trans-farnesol (Sigma Chemical Company, P. O. Box 14508, St. Louis, Missouri).
  • a suitable derivative of farnesol is farnesyl acetate which is commercially available from Aldrich Chemical Company, P. O. Box 2060, Milwaukee, WI.
  • Geraniol is the common name for the chemical known as 3,7-dimethyl-2,6-octadien-l-ol.
  • Geraniol includes isomers and tautomers of such. Geraniol is commercially available from Aldrich Chemical Company (P. O. Box 2060, Milwaukee, WI). Suitable derivatives of geraniol include geranyl acetate, geranylgeraniol, geranyl pyrophosphate, and geranylgeranyl pyrophosphate, all of which are commercially available from Sigma Chemical Company, P. O. Box 14508, St. Louis, MO.
  • geraniol is useful as a spider vessel/ red blotchiness repair agent, a dark circle/puffy eye repair agent, sallowness repair agent, a sagging repair agent, an anti-itch agent, a skin thickening agent, a pore reduction agent, oil/shine reduction agent, a post-inflammatory hyperpigmentation repair agent, wound treating agent, an anti-cellulite agent, and regulating skin texture, including wrinkles and fine lines.
  • Phytantriol is the common name for the chemical known as
  • Phytantriol is commercially available from BASF (1609 Biddle Avenue, Whyandotte, MI).
  • phytantriol is useful as a spider vessel/ red blotchiness repair agent, a dark circle/puffy eye repair agent, sallowness repair agent, a sagging repair agent, an anti-itch agent, a skin thickening agent, a pore reduction agent, oil/shine reduction agent, a post-inflammatory hyperpigmentation repair agent, wound treating agent, an anti-cellulite agent, and regulating skin texture, including wrinkles and fine lines.
  • Phytosterol and derivatives thereof are known for providing skin lightening benefits.
  • Non-limiting examples of oil-soluble phytosterol derivatives include ⁇ -sitosterol, campesterol, brassicasterol, lupenol, ⁇ -spinasterol, stigmasterol, their derivatives, and combinations thereof.
  • the phytosterol derivative is selected from the group consisting of ⁇ -sitosterol, campesterol, brassicasterol, stigmasterol, their derivatives, and combinations thereof.
  • oils-soluble vitamin compounds are useful as oil-soluble skin care actives herein.
  • oil-soluble vitamin compounds include retinoids, additional vitamin B 3 compounds, vitamin C (e.g. ascorbyl palmitate), vitamin D, vitamin K, vitamin E, and mixtures thereof.
  • retinoids retinoids, additional vitamin B 3 compounds, vitamin E, and mixtures thereof, each of which is discussed below.
  • retinoid includes all natural and/or synthetic analogs of Vitamin A or retinol-like compounds which possess the biological activity of Vitamin A in the skin as well as i the geometric isomers and stereoisomers of these compounds.
  • Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, retinyl propionate, retinal and combinations thereof, but any oil-soluble retinoid may be used herein.
  • compositions of the present invention may also include, in some embodiments, an additional vitamin B 3 compound (other than niacinamide).
  • an additional vitamin B 3 compound other than niacinamide.
  • the composition preferably includes from about 0.01% to about 50%, more preferably from about 0.1% to about
  • vitamin B3 compound 1% to about 5%, by weight of the composition, of the vitamin B3 compound.
  • additional vitamin B3 compound means a compound having the formula:
  • R is, - COOH (i.e., nicotinic acid) or - CH2OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
  • exemplary derivatives of the foregoing vitamin B3 compounds include nicotinic acid esters, including non- vasodilating esters of nicotinic acid (e.g., tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
  • Vitamin E and several derivatives thereof are known to be especially useful as anti- oxidants/radical scavengers.
  • Such antioxidants/radical scavengers are especially useful for providing protection against UV radiation which can cause increased scaling or texture changes in the stratum corneum and against other environmental agents which can cause skin damage.
  • Nonlimiting examples of oil soluble vitamin E compounds include tocopherol (vitamin
  • tocopherol sorbate tocopherol acetate
  • other esters of tocopherol Preferred anti- oxidants/radical scavengers are selected from tocopherol sorbate, tocopherol acetate, and mixtures thereof.
  • Also useful herein are the class of materials, tocotrienols, which are related to vitamin E.
  • Emollients are cosmetic ingredients which help to maintain the soft, smooth, and pliable appearance of skin. Emollients function by their ability to remain on the skin surface or in the stratum corneum to act as lubricants, to reduce flaking, and to improve the skin's appearance.
  • Occlusives are cosmetic ingredients which retard with the evaporation of water from the skin surface. By blocking the evaporative loss of water, occlusive materials increase the water content of skin. Occlusive agents are generally lipids which tend to remain on the skin surface. Emollients may also sometimes exhibit occlusive properties upon 1 application to the skin, and vice versa. Examples of suitable emollients and occlusives include Caprylic/Capric
  • Glycerides Isopropyl Isostearate, Mineral Oil, Cetyl Ricinoleate, and Petrolatum.
  • Dehydroacetic acid is a compound that is useful for regulating oily and/or shiny appearance of the skin, as disclosed in USP 6,150,403. Its chemical name is 3-Acetyl-6- methyl-2H-pyran-2,4(3H)-dione, and it can be commercially purchased from Universal Preserv- A-Chem of Brooklyn, NY under the tradename Unisept DHA®, from Tri-K Industries (Northvale, NJ), and under the tradename GEOGARD ® 221 or GEOGARD ® 361 from Lonza (Annandale, NJ).
  • compositions of the present invention may comprise from about 0.1% toa bout 10%, more preferably from about 0.5% to about 5%, and even more preferably from about 1% to about 5% of dehydroactic acid or dermatologically acceptable salts, derivatives, or tautomers thereof.
  • compositions of the present invention may comprise an effective amount of hexanediol, its isomers, tautomers, salts and derivatives.
  • hexanediol suitable for use herein include 1,6-dihydroxyhexane, 1,6-hexanediol, hexamethylenediol, hexamethylene glycol, and 1,2-hexanediol.
  • compositions of the present invention may comprise from about 0.0001% to about 50%, alternatively from about 0.001% to about 10%, alternatively from about 0.01% to about 5%, and alternatively from about 0.1 % to about 2% hexanediol.
  • compositions of the present invention may contain a safe and effective amount of one or more anti-acne actives.
  • useful anti-acne actives include resorcinol, sulfur, salicylic acid, benzoyl peroxide, erythromycin, zinc, etc.
  • Beta-Hvdroxy Acids include resorcinol, sulfur, salicylic acid, benzoyl peroxide, erythromycin, zinc, etc.
  • Nonlimiting examples of oil-soluble beta-hydroxy acids include salicylic acid and derivatives thereof such as the octanoyl derivative. Beta-hydroxy acids are known to provide anti-acne and anti-aging benefits.
  • chelator or "chelating agent” means an active agent capable of removing a metal ion from a system by forming a complex so that the metal ion cannot readily participate in or catalyze chemical reactions.
  • the inclusion of a chelating agent is especially useful for providing protection against UV radiation which can contribute to excessive scaling or skin texture changes and against other environmental agents which can cause skin damage.
  • Preferred oil-soluble chelators useful in compositions of the subject invention are furildioxime, furilmonoxime, and derivatives thereof. Flavonoids
  • Flavonoid compounds are broadly disclosed in U.S. Patents 5,686,082 and 5,686,367.
  • Nonlimiting examples of flavonoids useful herein include isoflavones, flavanones selected from the group consisting of unsubstituted flavanones, mono-substituted flavanones, and mixtures thereof; chalcones selected from the group consisting of unsubstituted chalcones, mono- substituted chalcones, di-substituted chalcones, fri-substituted chalcones, and mixtures thereof; flavones selected from the group consisting of unsubstituted flavones, mono-substituted flavones, di-substituted flavones, and mixtures thereof; one or more isoflavones; coumarins selected from the group consisting of unsubstituted coumarins, mono-substituted coumarins, di- substituted coumarins
  • substituted means flavonoids wherein one or more hydrogen atom of the flavonoid has been independently replaced with a hydroxyl, C1-C8 alkyl, or C1-C4 alkoxyl. Mixtures of the above flavonoid compounds may also be used.
  • Plant-derived isoflavones such as soy isoflavones are particularly useful herein.
  • a particularly useful type of flavonoid herein is glycoside flavonoid, preferably selected from the group consisting of glucosyl hesperidin, glucosyl rutin, glucosyl myricitrin, glucosyl isoquercitrin, glucosyl quercitirin, methyl hesperedin, and mixtures thereof.
  • Commercially available glycoside flavonoids include hesperidin, methyl hesperidin and rutin available from Alps Pharmaceutical Industry Co. Ltd. (Japan), and glucosyl hesperidin and glucosyl rutin available from Hayashibara Biochemical Laboratories, Inc.
  • a safe and effective amount of an anti-inflammatory agent may be added to the compositions of the present invention, preferably from about 0.1% to about 10%, more preferably from about 0.5% to about 5%, of the composition.
  • the anti-inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone or color.
  • the exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti-inflammatory agent utilized since such agents vary widely in potency.
  • l Steroidal anti-inflammatory agents including but not limited to hydrocortisone, are suitable for use herein.
  • Nonsteroidal anti-inflammatory agents including but not limited to ibuprofen, naproxen, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, piroxicam and felbinac, are also suitable for use herein.
  • the variety of compounds encompassed by these groups are well-known to those skilled in the art.
  • Mixtures of nonsteroidal anti-inflammatory agents may also be employed, as well as the dermatologically acceptable salts and esters of these agents.
  • Natural anti-inflammatory agents are also useful in the present invention. Such agents may suitably be obtained as an extract by suitable physical and/or chemical isolation from natural sources (e.g., plants, fungi, by-products of microorganisms) or can be synthetically prepared.
  • candelilla wax bisabolol (e.g., alpha bisabolol), aloe vera, plant sterols (e.g., phytosterol), Manjistha (extracted from plants in the genus Rubia, particularly Rubia Cordifolia), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora Mukul), kola extract, chamomile, red clover extract, and sea whip extract, may be used.
  • bisabolol e.g., alpha bisabolol
  • aloe vera e.g., plant sterols (e.g., phytosterol)
  • Manjistha extracted from plants in the genus Rubia, particularly Rubia Cordifolia
  • Guggal extracted from plants in the genus Commiphora, particularly Commiphora Mukul
  • kola extract chamomile
  • red clover extract and sea whip extract
  • compositions of the present invention may also contain a safe and effective amount of an anti-cellulite agent.
  • Suitable agents may include, but are not limited to, xanthine compounds (e.g., caffeine, theophylline, theobromine, and aminophylline).
  • Topical Anesthetics The compositions of the present invention may also contain a safe and effective amount of a topical anesthetic.
  • topical anesthetic drugs examples include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexyl- caine, procaine, cocaine, ketamine, pramoxine, phenol, and pharmaceutically acceptable salts thereof.
  • Desquamation Actives A safe and effective amount of a desquamation active may be added to the compositions of the present invention, preferably from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, even more preferably from about 0.5% to about 4%, by weight of the composition. Desquamation actives enhance the skin appearance benefits of the present invention. For example, the desquamation actives tend to improve the texture of the skin (e.g., smoothness).
  • One desquamation system that is suitable for use herein contains sulfhydryl compounds and zwitterionic surfactants and is described in U.S. Patent No. 5,681,852, to Bissett, incorporated herein by reference.
  • Another desquamation system that is suitable for use herein contains salicylic acid and zwitterionic surfactants and is described in U.S. Patent No. 5,652,228 to Bissett, incorporated herein by reference. Zwitterionic surfactants such as described in these applications are also useful as desquamatory agents herein, with cetyl betaine being particularly preferred.
  • compositions of the present invention may include a safe and effective amount of an anti-oxidant/radical scavenger.
  • the anti-oxidant/radical scavenger is especially useful for providing protection against UV radiation which can cause increased scaling or texture changes in the stratum corneum and against other environmental agents which can cause skin damage.
  • a safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 0.1% to about 5%, of the composition.
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, BHT, 6- hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox ), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., ,N,N- diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g.
  • Preferred anti- oxidants/radical scavengers are selected from tocopherol acetate and other esters of tocopherol, more preferably tocopherol acetate.
  • tocopherol sorbate in topical compositions and applicable to the present invention is described in U.S. Patent No. 4,847,071, issued on July 11, 1989 to Donald L. Bissett, Rodney D. Bush and Ranjit Chatterjee.
  • compositions of the present invention may contain a tanning active.
  • a tanning active When present, it is preferable that the compositions contain from about 0.1% to about 20%, more preferably from about 2% to about 7%, and still more preferably from about 3% to about 6%, by weight of the composition, of dihydroxyacetone as an artificial tanning active.
  • Dihydroxyacetone which is also known as DHA or l,3-dihydroxy-2-propanone, is a white to off-white, crystalline powder. This material can be represented by the chemical formula C 3 H 6 O 3 .
  • compositions of the present invention may include a skin soothing or skin healing active.
  • Skin soothing or skin healing actives suitable for use herein include panthenoic acid derivatives (including panthenol, dexpanthenol, ethyl panthenol), aloe vera, allantoin, bisabolol, and dipotassium glycyrrhizinate.
  • a safe and effective amount of a skin soothing or skin healing active may be added to the present composition, preferably, from about 0.001% to about 30%, more preferably from about 0.01% to about 20%, still more preferably from about 0.01% to about 10%, by weight of the composition formed.
  • compositions of the present invention may contain an antimicrobial or antifungal active.
  • actives are capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes and are known to those of skill in the art.
  • a safe and effective amount of an antimicrobial or antifungal active may be added to the present compositions, preferably, from about 0.001% to about 10%, more preferably from about 0.01% to about 5%, and still more preferably from about 0.05% to about 2%.
  • oils-soluble actives are used for purpose of sunscreen, whitening, anti-oxidant, etc, an ester may be used as a solvent to ensure efficacy of the oil-soluble active(s).
  • suitable ester compounds include esters of amino acids and C2 -C8 alcohols such as Isopropyl Lauroyl Sarcosinate (Eldew SL205 from Ajinomoto), and esters of benzoic acid and C2 -C8 alcohols such as Phenethyl Benzoate (X-tend 226 from International Specialty Products).
  • the level of solvent to be used will depend on the type and amount oil-soluble active to be incorporated and can readily be determined by those of skill in the art.
  • Optional Ingredients A variety of additional ingredients can be incorporated into the compositions of the present invention.
  • additional ingredients include; colorants, dyes, pigments; agents suitable for aesthetic purposes such as essential oils, fragrances, skin sensates, opacifiers, aromatic compounds (e.g., clove oil, menthol, camphor, eucalyptus oil, and eugenol); preservatives (e.g.
  • alkyl esters of para-hydroxybenzoic acid hydantoin derivatives such as 1,3- bis(hydroxymethyl)-5,5-dimthylhydantoin, propionate salts, and a variety of quaternary ammonium compounds such as benzalkonium chloride, quaternium 15 [Dowicil 200], benzethonium Chloride, and methylbenzethonium chloride).
  • Particularly preferred preservatives are disodium EDTA, phenoxyethanol, ethyl paraben, methyl paraben, propyl paraben, imidazolidinyl urea (commercially available as Germall 1157), sodium dehydroacetate, benzyl alcohol_and sodium benzoate.
  • compositions useful for the methods of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
  • compositions of the present invention may be formulated into a facial skin cosmetic, eye cosmetic, lip cosmetic, scalp hair styling aid, facial hair styling aid, moisturizer, wrinkle soothing serum, lotion, mascara, skin facial mask, skin lotion, skin cream, skin gel, eye gel, eye cream, lip gel, lip cream, cosmetic, foundation, or any other commonly known skin product or treatment.
  • compositions of the present invention are useful in a variety of applications directed to enhancement of mammalian skin.
  • the methods of use for the compositions disclosed and claimed herein include, but are not limited to: 1) methods of increasing the substantivity of a cosmetic to skin; 2) methods of moisturizing skin; 3) methods of improving the natural appearance of skin; 4) methods of applying a color cosmetic to skin; 5) methods of preventing, retarding, and/or treating wrinkles; 6) methods of providing UV protection to skin; 7) methods of preventing, retarding, and/or controlling the appearance of oil; 8) methods of modifying the feel and texture of skin; 9) methods of providing even skin tone; 10) methods of preventing, retarding, and/or treating the appear of spider vessels and varicose veins; 11) methods of masking the appearance of vellus hair on skin; and 12) methods of concealing blemishes and/or imperfections in human skin, including acne, age spots, freckles, moles, scars, under eye circles, birth marks, post-inflammatory
  • Water in Oil emulsion skin care products are prepared by conventional methods from the following components.
  • KF96A (6cs). Available from Shin-Etsu, Tokyo, Japan.
  • Tospearl 145 A, CF 600, or 2000 available from GE Advanced Materials, Wilton, CT.
  • PEG-10 Dimethicone Available from Shin-Etsu, Tokyo, Japan.
  • Polyglyceryl-3 Polydimethylsiloxyethyl Dimethicone Available from Shin-Etsu, Tokyo, Japan.
  • Palmitoyl Pentapeptide-3 in water Available from Sederma, Edison, NJ.
  • DMDM Hydantoin Iodopropynyl butylcarbamate, 1,3 butylenel glycol in water. Available from Lonza Inc., Basel, Switzerland.
  • a suitable mixer e.g., Anchor blade, propeller blade, IKA T25.
  • Phase B Phase A
  • Phase A Phase A
  • a suitable mixer e.g., Anchor blade, propeller blade, IKA T25. Maintain mixing until batch is uniform.
  • Microscopy Method - This method is a microscope-assisted visual analysis of the presence and size of the water domains within a sample composition.
  • the method uses a standard optical microscope with Differential Interference Contrast and Crossed Polarized Light capabilities and a optical shear stage.
  • cross polarization may be used for sample compositions that have low translucency or for characterization of the watery domains. With the cross polarization technique, watery domains will appear dark in the resulting image.
  • a suitable configuration includes a Zeiss Axioplan 2 microscope (available from Carl Zeiss, Inc, Thornwood, NY) coupled with a MTI 3CCD camera (available from DAGE-MTI, Michigan City, IN).
  • Images are acquired using Metamorph software version 6.1 (available from Molecular Devices Corporation, Sunnyvale, CA) that is used to measure droplet size and save the resulting image.
  • the microscope is paired with a CSS450 optical shear stage (available from Linkam Scientific Instruments, Surrey, UK).
  • the microscope is configured to provide 50Ox magnification.
  • About 1.5 g of the emulsion (“Sample”) is carefully loaded onto the shear stage to minimize shear.
  • the shear system is configured for a steady mode having a gap width of lmm and a constant shear rate of 16 s "1 . Temperature is held constant at approximately 25 0 C.
  • An initial micrograph is captured of the Sample prior to initiation of shear by the shear stage.
  • the sample should have an average water droplet size of about 3 microns or less. If a Sample exhibits an average water droplet size of greater than 3 microns, the Sample may not be properly characterized by microscopy; however, the Sample may be characterized by the Milling method or the Rheological method.
  • the visible water domains of the Sample are analyzed to provide a maximum linear dimension for each of the visible water domains.
  • Figs. IA-B are micrographs of Example 13 taken at 0 seconds and 15 seconds, respectively.
  • Fig. IB shows an aqueous domain of approximately 74.05 ⁇ m after 15 seconds of shear.
  • Figs. 2A-C are micrographs of Example 12 taken at 0 seconds, 15 seconds, and 60 seconds, respectively.
  • Fig. 2C shows an aqueous domain of approximately 56.04 ⁇ m after 60 seconds of shear.
  • Figs. 3A-C are micrographs of a Comparative Example (commercially available Regenerist Daily Regenerating Serum available from The Procter & Gamble Company) taken at 0 seconds, 15 seconds, and 60 seconds, respectively.
  • Fig. 3C shows silicone elastomer domains that are readily characterized to a skilled microscopist; however, no aqueous domains greater than lO ⁇ m are present.
  • Milling Method- This method involves the bulk milling of the sample emulsion ("Sample") to yield a visible (to the naked eye) phase separation.
  • the milling method involves the bulk milling of a 30g Sample in 50 mL beaker using an Ultra Turrax T25 mixer with a S 25 KR- 18 G dispersing element available from IKA Works, Wilmington, NC. The method is conducted at a temperature of approximately 25°C.
  • the Sample is milled for about 1 minute at a speed of either about 13500 rpm (which corresponds to a shear rate of about 30000 s "1 ) or about 24000 rpm (which corresponds to a shear rate of about 53000 s "1 ).
  • the beaker may be gently (i.e., reciprocating motion of no more than about 1 Hz) moved by hand in a direction parallel to the rotor axis of the mixer.
  • a Sample may be milled at a speed of 8000 rpm (which corresponds to a shear rate of about 18000 s "1 ).
  • phase separation is visually observed.
  • the aqueous phase is removed from the beaker using standard separation techniques.
  • the separated aqueous phase is weighed. The method is repeated with two additional samples and the weights are averaged.
  • the Comparative Example is the commercially available Regenerist Daily Regenerating Serum available from The Procter & Gamble Company.
  • Rheological Method - This method provides a rheological profile for the emulsion ("Sample").
  • the Sample is evaluated using an AR 2000 Rheometer available from TA Instruments, New Castle, DE that is interfaced with a computer having software that provides data recordation and analysis.
  • the rheometer is configured with 4 cm flat plates at a gap setting of 1000 microns, a temperature of 25 0 C, and in a controlled stress mode.
  • the rheometer is configured to ramp stress from IPa to lOOOPa with a duration of 3 minutes and to sample at a rate of 10 points per decade.
  • a rheology profile is plotted using the logio viscosity (Pa-s) on the y-axis versus the logio shear stress (Pa) on the x-axis.
  • Water-releasing Samples exhibit a sharp decrease in viscosity at a critical shear stress. This decrease in viscosity may be measured as the slope of the plot between the regions wherein the viscosity has a substantially constant high viscosity and a substantially constant lower viscosity.
  • the slope is calculated according to the formula [(log viscosity(t2) - log viscosity(tl)]/[(log shear stress(t2) - log shear stress (tl)], where viscosity (tl) and viscosity (t2) are the viscosity readings before and after the viscosity value
  • Figs. 4-7 Graphs of the resulting data for C select examples tested according to the rheological method are provided in Figs. 4-7.
  • Fig. 4 is the graph that results from Example 12.
  • Fig. 4 shows a steep drop in viscosity (e.g., slope of about -106) between data points at a shear stress of approximately 1.8 (log).
  • Fig. 5 is the graph that results from Example 11.
  • Fig. 5 shows a drop in viscosity (e.g., slope of about -14.7) between data points at a shear stress of approximately 0.8 (log).
  • Fig. 6 is the graph that results from Example 10.
  • Fig. 6 shows a drop in viscosity (e.g., slope of about -12) between data points at a shear stress of approximately 1.7 (log).
  • Fig. 7 is the graph that results from testing a Comparative Example (commercially available Regenerist Daily Regenerating Serum available from The Procter & Gamble Company). The largest

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La présente invention concerne des compositions d'émulsion d'eau dans l'huile comprenant : d'environ 0,1 % à environ 15 % d'un élastomère de siloxane réticulé non émulsifiant ; d'environ 0,1 % à environ 15 % d'un élastomère de siloxane réticulé émulsifiant ; d'environ 1 % à environ 40 % d'un solvant pour les élastomères de siloxane réticulés non émulsifiant et émulsifiant ; éventuellement, de 0 % à environ 5 % d'un émulsifiant supplémentaire ; et d'environ 50 % à environ 99 % de phase aqueuse ; caractérisées en ce que, lorsqu'une contrainte de cisaillement est appliquée à la composition durant l'étalement sur la peau, la phase aqueuse est libérée de l'émulsion.
EP06844620A 2005-12-02 2006-11-30 Compositions d'emulsion d'eau dans l'huile contenant des elastomeres de siloxane Withdrawn EP1979054A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74207305P 2005-12-02 2005-12-02
US80055406P 2006-05-15 2006-05-15
US81279106P 2006-06-12 2006-06-12
PCT/US2006/045657 WO2007064687A1 (fr) 2005-12-02 2006-11-30 Compositions d'emulsion d'eau dans l'huile contenant des elastomeres de siloxane

Publications (1)

Publication Number Publication Date
EP1979054A1 true EP1979054A1 (fr) 2008-10-15

Family

ID=37820579

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06844620A Withdrawn EP1979054A1 (fr) 2005-12-02 2006-11-30 Compositions d'emulsion d'eau dans l'huile contenant des elastomeres de siloxane

Country Status (5)

Country Link
EP (1) EP1979054A1 (fr)
JP (1) JP2009517478A (fr)
KR (1) KR101171803B1 (fr)
CA (1) CA2629853A1 (fr)
WO (1) WO2007064687A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230954B2 (ja) * 2007-02-15 2013-07-10 株式会社コーセー 油中水乳化型日焼け止め料
US20080311058A1 (en) * 2007-06-18 2008-12-18 Connopco, Inc., D/B/A Unilever Stable high internal phase emulsions and compositions comprising the same
US20090011035A1 (en) * 2007-07-03 2009-01-08 Joseph Michael Zukowski Personal care composition
JP2012509322A (ja) * 2008-11-24 2012-04-19 ザ プロクター アンド ギャンブル カンパニー 化粧品組成物
JP5667383B2 (ja) * 2009-06-19 2015-02-12 花王株式会社 油中水型乳化化粧料
US20110033512A1 (en) * 2009-08-10 2011-02-10 Laurie Ellen Breyfogle Personal care composition with improved spreadability
JP5610739B2 (ja) * 2009-10-30 2014-10-22 株式会社ミルボン 高内水相油中水型毛髪処理剤及びこれを収容した容器
FR2954104B1 (fr) * 2009-12-18 2012-03-09 Oreal Emulsion e/h comprenant un elastomere de silicone emulsionnant et un alcane lineaire volatil
JP5892720B2 (ja) * 2010-04-06 2016-03-23 株式会社ノエビア 皮膚外用剤
US8821839B2 (en) 2010-10-22 2014-09-02 Conopco, Inc. Compositions and methods for imparting a sunless tan with a vicinal diamine
JP2013116870A (ja) * 2011-12-02 2013-06-13 Rohto Pharmaceutical Co Ltd 皮膚外用組成物
US8961942B2 (en) 2011-12-13 2015-02-24 Conopco, Inc. Sunless tanning compositions with adjuvants comprising sulfur comprising moieties
JP5373046B2 (ja) * 2011-12-19 2013-12-18 株式会社 資生堂 水中油型乳化組成物
US20130345316A1 (en) * 2012-06-21 2013-12-26 L'oreal Water-releasing cosmetic composition
JP5974843B2 (ja) * 2012-11-13 2016-08-23 信越化学工業株式会社 シリコーン油中水型マクロエマルジョン化粧料組成物
JP2014097936A (ja) * 2012-11-13 2014-05-29 Shin Etsu Chem Co Ltd シリコーン油中水型マクロエマルジョン化粧料組成物
JP6685235B2 (ja) * 2013-12-20 2020-04-22 ロレアル 水溶性有効成分に対する担体システム
GB2525895A (en) * 2014-05-07 2015-11-11 Boots Co Plc Skin care composition
GB2525894A (en) * 2014-05-07 2015-11-11 Boots Co Plc Skin care composition
CN105168045B (zh) * 2015-09-07 2018-07-17 天津嘉氏堂科技有限公司 一种疤痕防晒修复硅凝胶及制备方法
US10413487B2 (en) 2015-12-01 2019-09-17 Shanghai O'Nine Technologies Ltd. Nail gel polish and its manufacturing method
CN105434187A (zh) * 2015-12-01 2016-03-30 上海零玖科技有限公司 一种甲油胶及其制备方法
CN109069383A (zh) * 2016-03-24 2018-12-21 拜尔克林兹Ph有限责任公司 与微生物生物膜相关的皮肤病状和疾病的治疗
JP2018087165A (ja) * 2016-11-29 2018-06-07 ロレアル 油中水エマルション組成物
US11510863B2 (en) 2016-12-21 2022-11-29 Shiseido Company, Ltd. Water-in-oil emulsion cosmetics
CN110662528B (zh) * 2017-05-25 2022-12-27 富士胶片株式会社 油包水型化妆材料
JP7356228B2 (ja) * 2018-01-31 2023-10-04 株式会社コーセー 組成物
JP6460504B1 (ja) * 2018-05-31 2019-01-30 株式会社コスモビューティー 油中水型エマルション組成物
JP7202159B2 (ja) * 2018-12-04 2023-01-11 ポーラ化成工業株式会社 粉体含有化粧料
US10959933B1 (en) * 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
KR102569047B1 (ko) * 2021-02-24 2023-08-23 한국콜마주식회사 비타민c를 고함량으로 포함하는 화장료 조성물
FR3130816B1 (fr) * 2021-12-17 2023-12-15 Elkem Silicones France Sas Composition silicone réticulable par irradiation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3671327B2 (ja) * 1998-09-14 2005-07-13 株式会社コーセー 油中水型化粧料
US6221979B1 (en) * 1999-11-08 2001-04-24 Dow Corning Corporation Mixtures of silicone elastomers
JP2002193754A (ja) * 2000-12-27 2002-07-10 Kose Corp 油中水乳化型毛髪用化粧料
US20040234477A1 (en) * 2001-09-14 2004-11-25 Koji Sakuta Composition and cosmetic preparation containing the same
US9090755B2 (en) * 2002-09-12 2015-07-28 Shin-Etsu Chemical Co., Ltd. Organopolysiloxane polymer, pasty composition, and cosmetic preparation containing the composition
JP3979922B2 (ja) 2002-11-08 2007-09-19 信越化学工業株式会社 親水化処理粉体及びこれらを含有する組成物
US7285570B2 (en) * 2003-04-17 2007-10-23 The Procter & Gamble Company Compositions and methods for regulating mammalian keratinous tissue
JP2004339106A (ja) * 2003-05-14 2004-12-02 Takashi Fukazawa 油中水型乳化組成物
JP2004346046A (ja) * 2003-05-26 2004-12-09 Shin Etsu Chem Co Ltd 化粧料
DE60334857D1 (de) * 2003-06-10 2010-12-16 Shinetsu Chemical Co Kosmetische zubereitung
JP5037782B2 (ja) * 2003-07-07 2012-10-03 信越化学工業株式会社 新規なオルガノポリシロキサン・グリセリン誘導体交互共重合体およびそれを含有する化粧料
JP2005041809A (ja) * 2003-07-28 2005-02-17 Nonogawa Shoji Kk Ｗ／ｏ乳化化粧料
JP4113093B2 (ja) * 2003-10-28 2008-07-02 ポーラ化成工業株式会社 アスコルビン酸類を含有する皮膚外用剤
JP2005179305A (ja) * 2003-12-22 2005-07-07 Lion Corp 制汗剤組成物
JP4520903B2 (ja) * 2005-06-02 2010-08-11 花王株式会社 油中水型乳化組成物
JP4993983B2 (ja) * 2005-09-28 2012-08-08 信越化学工業株式会社 オルガノポリシロキサン表面処理剤系及び該処理剤系で表面処理された粉体、並びに該粉体を含有する化粧料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007064687A1 *

Also Published As

Publication number Publication date
JP2009517478A (ja) 2009-04-30
KR101171803B1 (ko) 2012-08-13
WO2007064687A1 (fr) 2007-06-07
KR20080063851A (ko) 2008-07-07
CA2629853A1 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
US20070128137A1 (en) Water in oil emulsion compositions containing siloxane elastomers
KR101171803B1 (ko) 실록산 탄성중합체를 함유하는 유중수 에멀젼 조성물
US20070274932A1 (en) Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers
KR100833831B1 (ko) Ｎ-아실 아미노산 조성물을 이용한 포유류 각질 조직의조절
US8063097B2 (en) Compositions and methods for regulating mammalian keratinous tissue
US7175836B1 (en) Oil continuous phase cosmetic emulsions with conjugated linoleic acid
KR20030020916A (ko) 유용성 스킨 케어 활성제의 전달 향상 방법
US20080139453A1 (en) Multiple emulsion compositions
US20080299058A1 (en) Multi-formulation cosmetic compositions
CN101321561A (zh) 包含硅氧烷弹性体的油包水乳液组合物
CN101443081A (zh) 包含防晒活性物质和硅氧烷弹性体的油包水乳液组合物
AU2001271930B2 (en) Methods of enhancing delivery of oil-soluble skin care actives
AU2001271930A1 (en) Methods of enhancing delivery of oil-soluble skin care actives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20081215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101111